d-enantiomer amphetamine (dopaminergic-preferring)

Plain-language summaryIntrigue 65 / 100

Dextroamphetamine is the d-enantiomer of amphetamine, sold as Dexedrine since 1976. The d-form is roughly two to three times more potent at central dopamine release than the l-form, while both release norepinephrine about equally. The practical result is a stimulant tilted toward CNS dopamine effects with somewhat less peripheral cardiovascular load than racemic mixtures like Adderall. Approved for ADHD and narcolepsy. Schedule II. Used clinically when patients tolerate racemic amphetamine poorly and as the canonical pure d-amphetamine reference in research where investigators need to isolate the dopaminergic component of the response. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

41/100

Canonical d-amphetamine reference compound; settled pharmacology, limited frontier value, probe utility only

Dextroamphetamine is about as well-characterized as a compound gets in psychopharmacology. FDA approved in 1976, used clinically for ADHD and narcolepsy for nearly five decades; the literature here is enormous, the mechanism is settled, and the basic pharmacology has been picked over thoroughly. Thats not a knock on the compound: it’s just the reality of its place in the field.

The core story is well-known: d-amphetamine is approximately 2-3x more potent at central dopamine release than the l-enantiomer, while both enantiomers release norepinephrine at roughly equivalent rates. The net pharmacological profile versus racemic amphetamine is a cleaner CNS dopaminergic signal with reduced peripheral sympathomimetic activity. Mechanistically, this is monoamine reverse-transport via DAT, NET, and SERT: textbook amphetamine pharmacology, not something new.

Where it does retain value is as a research probe for pure d-amphetamine pharmacology. If you’re studying enantiomeric contributions to amphetamine effects, comparing d- versus l-amphetamine release dynamics, or using it as a reference standard in translational ADHD models, dextroamphetamine is the canonical compound. There’s no substitute for that specific role. The bench value score reflects this: genuinely useful in a narrow but legitimate context.

What we don’t love is that the interesting amphetamine-adjacent research isn’t really about dextroamphetamine per se anymore. The questions the field actually cares about now involve TAAR1 agonism and its emerging role in monoamine homeostasis, the pharmacogenomics of amphetamine response variability, and dual dopamine-serotonin releasers as novel depression targets. Dextroamphetamine is background context for those conversations, not the interesting variable in them. The differentiation score is modest for good reason: it’s the canonical probe, but the probe itself isn’t what’s being investigated.

Evidence quality is objectively high. This is an approved drug with extensive phase 3 data, multi-decade replication across independent labs, and clear translational signal for ADHD and narcolepsy. But high evidence quality for settled questions doesn’t make a compound compelling as a bench research target; it makes it a reference standard, which is a different thing entirely.

The Schedule II classification adds real logistical friction. DEA licensing, handling requirements, institutional overhead: none of this is insurmountable, but it shapes what a lab is actually going to reach for when designing a study. Combined with the saturation of the literature, there are very few questions a serious bench lab would be trying to answer with dextroamphetamine that haven’t already been answered decades ago. Honestly, it earns its score as a historical anchor and occasional enantiomeric probe; it doesnt earn more than that.

Novelty: 10
Mechanism promise: 20
In-category differentiation: 35
Evidence quality: 75
Translational signal: 75
Research bench value: 55

Rationale Decades-old Schedule II compound with thoroughly settled dopaminergic mechanism; scores high on evidence quality and translational signal for its approved indications but very low on novelty and differentiation, producing a moderate overall that reflects reference-standard status rather than active research frontier. Schedule II cap of 65 does not bind since calculated overall is 41.

d-enantiomer amphetamine (dopaminergic-preferring)

The d-enantiomer of amphetamine; a more dopaminergic stimulant than the racemic mixture, used in ADHD and narcolepsy.

Abstract

Dextroamphetamine ((S)-1-phenylpropan-2-amine, d-amphetamine; CAS 51-64-9; molecular formula C9H13N; molecular weight 135.21) is the d-enantiomer of amphetamine, approved by the FDA in 1976 (Dexedrine). The d-enantiomer is approximately 2 to 3 fold more potent at central dopamine release than the l-enantiomer; both enantiomers have approximately equivalent norepinephrine release. The pharmacology versus racemic amphetamine is shifted toward CNS dopaminergic effects with reduced peripheral cardiovascular activity. Approved indications: ADHD, narcolepsy. Plasma half-life is approximately 12 hours. Schedule II. Used as the canonical pure d-amphetamine in research and clinical practice for patients tolerating racemic amphetamine poorly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-380Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: d-enantiomer amphetamine (dopaminergic-preferring)

Dextroamphetamine

Abstract

Read the full monograph